MBII · Marrone Bio Innovations Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $11.10M | - | $9.86M | $12.60M | $11.04M | - | $8.83M | $12.18M | $9.65M | - |
| Cost of Revenue | $4.89M | - | $3.81M | $4.83M | $4.07M | - | $3.83M | $4.79M | $4.08M | - |
| Gross Profit | $6.21M | - | $6.05M | $7.77M | $6.97M | - | $5.00M | $7.38M | $5.57M | - |
| R&D | $2.87M | - | $2.99M | $2.58M | $2.29M | - | $2.86M | $2.08M | $2.88M | - |
| SG&A | $10.07M | - | $7.26M | $7.29M | $7.48M | - | $7.33M | $7.08M | $7.99M | - |
| Total Operating Expenses | $13.23M | - | $10.46M | $10.12M | $9.99M | - | $10.45M | $9.39M | $11.23M | - |
| D&A | $885.0K | - | $300.0K | $298.0K | $874.0K | - | $298.0K | $448.0K | $891.0K | - |
| Operating Income | ($7.02M) | - | ($4.41M) | ($2.36M) | ($3.03M) | - | ($5.45M) | ($2.01M) | ($5.66M) | - |
| Interest Expense | $551.0K | - | $372.0K | $355.0K | $393.0K | - | $405.0K | $331.0K | $337.0K | - |
| Income Tax | ($11.0K) | - | ($3.0K) | $3.0K | $41.0K | - | $37.0K | $46.0K | $34.0K | - |
| Net Income | ($7.60M) | - | ($4.95M) | ($3.04M) | ($3.26M) | - | ($6.06M) | ($2.87M) | ($7.02M) | - |
| EPS - Basic | ($0.04) | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.36M | $19.62M | $15.04M | $17.46M | $18.92M | $15.84M | $8.97M | $10.45M | $10.12M | $6.25M |
| Accounts Receivable | $12.11M | $13.21M | $12.99M | $14.50M | $13.53M | - | - | - | $10.42M | $5.92M |
| Inventory | $10.12M | $8.63M | $8.52M | $6.48M | $6.41M | $6.62M | $6.19M | $6.14M | $7.08M | $8.15M |
| Accounts Payable | $3.36M | $2.69M | $3.02M | $1.76M | $2.19M | $1.90M | $1.99M | $1.02M | $6.51M | $3.38M |
| Current Assets | $32.96M | $42.68M | $37.42M | $40.04M | $40.22M | $34.26M | $24.01M | $29.37M | $29.43M | $21.72M |
| Total Assets | $76.21M | $87.06M | $82.14M | $85.62M | $86.47M | $81.20M | $72.06M | $78.40M | $79.39M | $72.72M |
| Current Liabilities | $41.71M | $45.19M | $27.39M | $26.49M | $26.03M | $24.23M | $22.94M | $25.87M | $27.98M | $21.09M |
| Long-term Debt | $7.59M | $7.69M | $11.20M | $11.29M | $11.38M | $11.48M | $11.37M | $11.45M | $11.63M | $11.85M |
| Total Liabilities | $53.34M | $57.40M | $51.51M | $50.94M | $51.11M | $49.79M | $48.96M | $52.30M | $54.53M | $49.16M |
| Stockholders' Equity | $22.87M | $29.65M | $30.63M | $34.68M | $35.35M | $31.41M | $23.11M | $26.10M | $24.86M | $23.56M |
| Retained Earnings | ($364.97M) | ($357.37M) | ($352.06M) | ($347.11M) | ($344.08M) | ($340.82M) | ($336.61M) | ($330.54M) | ($327.67M) | ($320.65M) |
Cash Flow
| Line item | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($8.40M) | - | - | - | ($5.02M) | - | - | - | ($6.29M) | - |
| Investing Cash Flow | ($198.0K) | - | - | - | ($869.0K) | - | - | - | ($673.0K) | - |
| Financing Cash Flow | ($1.67M) | - | - | - | $8.97M | - | - | - | $10.83M | - |
| CapEx | $198.0K | - | - | - | $119.0K | - | - | - | $135.0K | - |
| Free Cash Flow | ($8.59M) | - | - | - | ($5.14M) | - | - | - | ($6.43M) | - |
Ratios
| Metric | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 | Q4 '20 | Q3 '20 | Q2 '20 | Q1 '20 | Q4 '19 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 55.9% | - | 61.4% | 61.7% | 63.1% | - | 56.7% | 60.6% | 57.7% | - |
| Operating margin | -63.3% | - | -44.7% | -18.7% | -27.4% | - | -61.7% | -16.5% | -58.6% | - |
| EBITDA margin | -55.3% | - | -41.7% | -16.3% | -19.5% | - | -58.3% | -12.8% | -49.4% | - |
| Net margin | -68.5% | - | -50.2% | -24.1% | -29.5% | - | -68.7% | -23.6% | -72.8% | - |
| Free cash flow margin | -77.4% | - | - | - | -46.5% | - | - | - | -66.6% | - |
| FCF / Net income | 1.13 | - | - | - | 1.57 | - | - | - | 0.92 | - |
| R&D / Revenue | 25.8% | - | 30.3% | 20.5% | 20.8% | - | 32.4% | 17.0% | 29.8% | - |
| SG&A / Revenue | 90.7% | - | 73.7% | 57.9% | 67.8% | - | 83.1% | 58.1% | 82.8% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.0% | - | -6.0% | -3.5% | -3.8% | - | -8.4% | -3.7% | -8.8% | - |
| Return on equity | -33.2% | - | -16.1% | -8.8% | -9.2% | - | -26.2% | -11.0% | -28.2% | - |
| Return on invested capital | -18.2% | - | -8.3% | -4.0% | -5.1% | - | -12.5% | -4.2% | -12.2% | - |
| Liquidity | ||||||||||
| Current ratio | 0.79 | 0.94 | 1.37 | 1.51 | 1.54 | 1.41 | 1.05 | 1.14 | 1.05 | 1.03 |
| Quick ratio | 0.55 | 0.75 | 1.05 | 1.27 | 1.30 | 1.14 | 0.78 | 0.90 | 0.80 | 0.64 |
| Cash ratio | 0.22 | 0.43 | 0.55 | 0.66 | 0.73 | 0.65 | 0.39 | 0.40 | 0.36 | 0.30 |
| Leverage | ||||||||||
| Debt / Equity | 0.33 | 0.26 | 0.37 | 0.33 | 0.32 | 0.37 | 0.49 | 0.44 | 0.47 | 0.50 |
| Debt / Assets | 0.10 | 0.09 | 0.14 | 0.13 | 0.13 | 0.14 | 0.16 | 0.15 | 0.15 | 0.16 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -12.7x | - | -11.8x | -6.6x | -7.7x | - | -13.4x | -6.1x | -16.8x | - |
| Equity multiplier | 3.33 | 2.94 | 2.68 | 2.47 | 2.45 | 2.59 | 3.12 | 3.00 | 3.19 | 3.09 |
| Liabilities / Assets | 0.70 | 0.66 | 0.63 | 0.59 | 0.59 | 0.61 | 0.68 | 0.67 | 0.69 | 0.68 |
| Efficiency | ||||||||||
| Asset turnover | 0.15 | - | 0.12 | 0.15 | 0.13 | - | 0.12 | 0.16 | 0.12 | - |
| Inventory turnover | 0.48 | - | 0.45 | 0.75 | 0.63 | - | 0.62 | 0.78 | 0.58 | - |
| Days sales outstanding | 398d | - | 481d | 420d | 448d | - | - | - | 394d | - |
| Days inventory outstanding | 755d | - | 817d | 490d | 575d | - | 591d | 467d | 633d | - |
| Days payable outstanding | 251d | - | 290d | 133d | 196d | - | 189d | 78d | 582d | - |
| Cash conversion cycle | 903d | - | 1008d | 777d | 826d | - | - | - | 445d | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 0.5% | - | 11.6% | 3.4% | 14.4% | - | 62.7% | 74.0% | 10.7% | - |
| Revenue CAGR (3y) | 8.4% | - | 22.0% | 29.9% | 36.7% | - | 27.9% | 23.4% | 32.4% | - |
| Revenue CAGR (5y) | 21.7% | - | 22.1% | 20.1% | 32.8% | - | 29.0% | 29.4% | 36.2% | - |
| Gross profit growth (YoY) | -10.9% | - | 20.9% | 5.2% | 25.1% | - | 39.5% | 93.9% | 11.7% | - |
| Operating income growth (YoY) | -132.1% | - | 19.0% | -17.4% | 46.5% | - | 44.3% | 68.8% | -55.9% | - |
| Net income growth (YoY) | -132.9% | - | 18.4% | -5.7% | 53.6% | - | 63.0% | 57.5% | -79.3% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -67.3% | - | - | - | 20.1% | - | - | - | 34.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -35.3% | -5.6% | 32.6% | 32.9% | 42.2% | 33.3% | -5.9% | 646.6% | 159.6% | 82.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$44.31M totalProduct$43.81M · 98.9%
License$498.0K · 1.1%
Peer comparison
Same SIC group: Agricultural Chemicals
Comparing MARRONE BIO INNOVATIONS INC against the 5 most active filers in the same SIC group.